Article
The Dynamics of Interactions Among Immune and Glioblastoma Cells.
Neuromolecular medicine - 1 Dec 2015
Eder Katalin, Kalman Bernadette
Abstract excerpt
Glioblastoma is the most common intracranial malignancy that constitutes about 50 % of all gliomas. Despite aggressive, multimodal therapy consisting of surgery, radiation, and chemotherapy, the outcome of patients with glioblastoma remains poor with 5-year survival rates of <10 %. Resistance to conventional therapies is most likely caused by several factors. Alterations in the functions of local immune mediators...
Topics
Join the communities discussing this publication.